The study is designed to evaluate efficacy of topically applied PH-10 in a total of 25 subjects. In the study, PH-10 will be topically applied twice weekly for up to 12 weeks. Response will be observed for 16 weeks. The study is being conducted at the Mount Sinai School of Medicine in New York and is expected to require nine months to complete.
Craig Dees, CEO of Provectus, said: “We are pleased to offer patients with moderate to severe psoriasis the opportunity to participate in the Phase II clinical trial of PH-10, which we hope will prove to be more efficacious and safer than currently existing products.
“If the study proves to be as successful as we expect, topical PH-10 could be extremely advantageous in the treatment of psoriasis, a large underserved market in which current, highly expensive treatments may be efficacious but have a number of side effects including infections and risk of cancer.”